NASDAQ:SOLY - Soliton Stock Price, Forecast & News

Soliton trades on the NASDAQ under the ticker symbol "SOLY."

1 analysts have issued twelve-month price objectives for Soliton's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate Soliton's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price. View Analyst Price Targets for Soliton.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soliton in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soliton.

Headlines about SOLY stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soliton earned a news sentiment score of -3.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Soliton.

Soliton saw a decline in short interest in January. As of January 15th, there was short interest totalling 1,130,000 shares, a decline of 5.0% from the December 31st total of 1,190,000 shares. Based on an average trading volume of 214,800 shares, the short-interest ratio is presently 5.3 days. Approximately 17.8% of the company's stock are short sold. View Soliton's Current Options Chain.

Some companies that are related to Soliton include Intersect ENT (XENT), Orthofix Medical (OFIX), MiMedx Group (MDXG), Cerus (CERS), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Soliton investors own include Cronos Group (CRON), Canopy Growth (CGC), NVIDIA (NVDA), Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Micron Technology (MU), Verizon Communications (VZ), Tesla (TSLA), Innovative Industrial Properties (IIPR) and Square (SQ).

Soliton's stock is owned by many different of retail and institutional investors. Top institutional shareholders include University of Texas Texas AM Investment Managment Co. (2.51%), Geode Capital Management LLC (0.51%), State Street Corp (0.49%), Advisor Group Inc. (0.41%), First Republic Investment Management Inc. (0.28%) and Oxford Asset Management LLP (0.11%).

SOLY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Virtu Financial LLC.

SOLY stock was purchased by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., State Street Corp, First Republic Investment Management Inc., Oxford Asset Management LLP, Integrated Advisors Network LLC, Advisor Group Inc., Geode Capital Management LLC and UBS Group AG.

Shares of SOLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SOLY stock can currently be purchased for approximately $12.77.

Soliton has a market capitalization of $216.20 million. Soliton employs 7 workers across the globe.View Additional Information About Soliton.

The official website for Soliton is http://www.soliton.com/.

Soliton's mailing address is 5304 ASHBROOK DRIVE, HOUSTON TX, 77081. The company can be reached via phone at 844-705-4866.